Early pregnancy angiogenic proteins levels and pregnancy related hypertensive disorders

References

• Hutcheon JA, Lisonkova S, Joseph KS. Epidemiology of pre-eclampsia and the other hypertensive disorders of pregnancy. Best Pract Res Clin Obstet Gynaecol 2011;25:391–403
   PubMed Web of Science ®Google Scholar
• Ghulmiyah L, Sibai B. Maternal mortality from preeclampsia/eclampsia. Semin Perinatol 2012;36:56–9
   PubMed Web of Science ®Google Scholar
• Gaillard R, Arends LR, Steegers AP, et al. Second- and third-trimester placental hemodynamics and the risks of pregnancy complications: the generation R study. Am J Epidemiol 2013;177:743–54
   PubMed Web of Science ®Google Scholar
• Ferrazzani S, Luciano R, Garofalo S, et al. Neonatal outcome in hypertensive disorders of pregnancy. Early Hum Dev 2011;87:445–9
   PubMed Web of Science ®Google Scholar
• Gilbert JS, Ryan MJ, LaMarca BB, et al. Pathophysiology of hypertension during preeclampsia: linking placental ischemia with endothelial dysfunction. Am J Physiol Heart Circ 2008;294:541–50
   PubMed Web of Science ®Google Scholar
• Young BC, Richard J, Levine R, Karumanchi A. Pathogenesis of preeclampsia. Annu Rev Pathol Mech Dis 2010;5:173–92
   PubMed Web of Science ®Google Scholar
• Powe CE, Levine JR, Karumanchi SA. Preeclampsia, a disease of the maternal endothelium: the role of antiangiogenic factors and implications for later cardiovascular disease. Circulation 2011;123:2856–69
   PubMed Web of Science ®Google Scholar
• Rana S, Powe CE, Salahuddin S, et al. Angiogenic factors and the risk of adverse outcomes in women with suspected preeclampsia. Circulation 2012;125:911–9
   PubMed Web of Science ®Google Scholar
• Kusanovic JP, Romero R, Chaiworapongsa T, et al. A prospective cohort study of the value of maternal plasma concentrations of angiogenic and anti-angiogenic factors in early pregnancy and midtrimester in the identification of patients destined to develop preeclampsia. J Matern Fetal Neonatal Med 2009;22:1021–38
   PubMed Web of Science ®Google Scholar
• Noori M, Donald AE, Angelakopoulou A, et al. Prospective study of placental angiogenic factors and maternal vascular function before and after preeclampsia and gestational hypertension. Circulation 2010;122:478–87
   PubMed Web of Science ®Google Scholar
• Romero R, Nien JK, Espinoza J, et al. A longitudinal study of angiogenic (placental growth factor) and anti-angiogenic (soluble endoglin and soluble vascular endothelial growth factor receptor-1) factors in normal pregnancy and patients destined to develop preeclampsia and deliver a small for gestational age neonate. J Matern Fetal Neonatal Med 2008;21:9–23
   PubMed Web of Science ®Google Scholar
• Ahmed A. New insights into the etiology of preeclampsia: identification of key elusive factors for the vascular complications. Thromb Res 2011;127:72–5
   PubMed Web of Science ®Google Scholar
• Thadhani R, Kisner T, Hagmann H, et al. Pilot study of extracorporeal removal of soluble fms-like tyrosine kinase 1 in preeclampsia. Circulation 2011;124:940–50
   PubMed Web of Science ®Google Scholar
• Lu J, Zhao YY, Qiao J, et al. A follow-up study of women with a history of severe preeclampsia: relationship between metabolic syndrome and preeclampsia. Chin Med J (Engl) 2011;124:775–9
   PubMed Web of Science ®Google Scholar
• Lei Q, Lv LJ, Zhang BY, et al. Ante-partum and post-partum markers of metabolic syndrome in pre-eclampsia. J Hum Hypertens 2011;25:11–7
   PubMed Web of Science ®Google Scholar
• Akolekar R, Syngelaki A, Sarquis R, et al. Prediction of early, intermediate and late pre-eclampsia from maternal factors, biophysical and biochemical markers at 11-13 weeks. Prenat Diagn 2011;31:66–74
   PubMed Web of Science ®Google Scholar
• Lapaire O, Shennan A, Stepan H. The preeclampsia biomarkers soluble fms-like tyrosine kinase-1 and placental growth factor: current knowledge, clinical implications and future application. Eur J Obstet Gynecol Reprod Biol 2010;151:122–9
   PubMed Web of Science ®Google Scholar
• McKeeman GC, Ardill JE, Caldwell CM, et al. Soluble vascular endothelial growth factor receptor-1 (sFlt-1) is increased throughout gestation in patients who have preeclampsia develop. Am J Obstet Gynecol 2004;191:1240–6
   PubMed Web of Science ®Google Scholar
• Thadhani R, Mutter WP, Wolf M, et al. First trimester placental growth factor and soluble fms-like tyrosine kinase 1 and risk for preeclampsia. J Clin Endocrinol Metab 2003;89:770–5
   Web of Science ®Google Scholar
• Schneuer FJ, Nassara N, Guilberta C, et al. First trimester screening of serum soluble fms-like tyrosine kinase-1 and placental growth factor predicting hypertensive disorders of pregnancy. Pregnancy Hypertens 2013;3:215–21
   PubMed Web of Science ®Google Scholar
• Powers RW, Roberts JM, Cooper KM, et al. Maternal serum soluble fms-like tyrosine kinase 1 concentrations are not increased in early pregnancy and decrease more slowly postpartum in women who develop preeclampsia. Am J Obstet Gynecol 2005;193:185–91
   PubMed Web of Science ®Google Scholar
• Silasi M, Cohen B, Karumanchi A, Sarosh R. Abnormal placentation, angiogenic factors, and the pathogenesis of preeclampsia. Obstet Gynecol Clin North Am 2010;37:239–53
   PubMed Web of Science ®Google Scholar
• Molvarec A, Szarka A, Walentin S, et al. Circulating angiogenic factors determined by electrochemiluminescence immunoassay in relation to the clinical features and laboratory parameters in women with preeclampsia. Hypertens Res 2010;33:892–8
   PubMed Web of Science ®Google Scholar
• Livingston JC, Chin R, Haddad B, et al. Reductions of vascular endothelial growth factor and placental growth factor concentrations in severe preeclampsia. Am J Obstet Gynecol 2000;183:1554–7
   PubMed Web of Science ®Google Scholar
• Troisi R, Braekke K, Harsem NK, et al. Blood pressure augmentation and maternal circulating concentrations of angiogenic factors at delivery in preeclamptic and uncomplicated pregnancies. Am J Obstet Gynecol 2008;199:653.e1–653.10
   PubMed Web of Science ®Google Scholar
• Wolf M, Kettyle E, Sandler L, et al. Obesity and pre-eclampsia: potential role of inflammation. Obstet Gynecol 2001;1:757–62
   Google Scholar
• Thilaganathan B, Wormald B, Zanardini C, et al. Early-pregnancy multiple serum markers and second-trimester uterine artery Doppler in predicting pre-eclampsia. Am J Perinatol 2010;27:631–40
   PubMed Web of Science ®Google Scholar
• Bodnar LM, Catov JM, Klebanoff MA, et al. Prepregnancy body mass index and the occurrence of severe hypertensive disorders of pregnancy. Epidemiology 2007;18:234–9
   PubMed Web of Science ®Google Scholar
• Marshall NE, Guild C, Cheng YW, et al. Racial disparities inpregnancy outcomes in obese women. J Matern Fetal Neonatal Med 2014;27:122–6
   PubMed Web of Science ®Google Scholar
• Alves E, Azevedo A, Rodrigues T, et al. Impact of risk factors on hypertensive disorders in pregnancy, in primiparae and multiparae. Ann Hum Biol 2013;40:377–84
   PubMed Web of Science ®Google Scholar
• Spencer K, Cowans NJ, Nicolaides KH. Low levels of maternal serum PAPP-A in the first trimester and the risk of pre-eclampsia. Prenat Diagn 2008;28:7–10
   PubMed Web of Science ®Google Scholar
• Gioetzinger KR, Singla A, Gerkowic S, et al. Predicting the risk of pre-eclampsia between 11 and 13 weeks gestation by combining maternal characteristics and serum analytes, PAPP-A and free β-hCG. Prenat Diagn 2010;30:1138–42
   PubMed Web of Science ®Google Scholar